Top 10 Biotechnology Companies in the USA

Top 10 Biotechnology Companies in the USA

Top 10 Biotechnology Companies in the USA

Top 10 Biotechnology Companies in the USA

When considering total market value, biotechnology is consistently ranked among the top industrial subfields.

It is a broad topic that encompasses a variety of subfields, including research and development in the medical profession, genetic research, and bioengineering, as well as advancements in food and agriculture-based enterprises.

Over the last ten years, hundreds of new biotech companies have been founded in the United States alone.

Biotechnology companies are businesses that utilize biotechnological processes for production, distribution, and design.

Biotechnology is a field of technology that uses biological systems to produce goods and services. The biotech industry in the United States is a tiny but rapidly expanding segment of the pharmaceutical industry.

The pharmaceutical industry is buzzing with activity, from high-priced pharmaceuticals to the launch of biosimilars (drugs meant to be identical to those already on the market), which are expected to disrupt the industry by making treatment more inexpensive.

The nation's biotechnology firms can generate creative solutions, resulting in attractive biotechnology stock prices. Now, let we talk about the top 10 Biotechnology Companies in the USA.

Top 10 Biotechnology Companies in the USA

Several of these companies conduct biopharmaceutical research to advance drug innovation, development, and commercialization.

Others supply genomics and proteomics services, lab supplies, reagents, and instruments. Below is a list of the Top 10 Biotechnology Companies in the USA.

Kiniksa Pharmaceuticals

Kiniksa is a publicly traded biopharmaceutical firm specializing in the discovery, acquisition, development, and commercialization of therapeutic medications for patients suffering from chronic diseases with considerable unmet medical needs.

We have a pipeline of autoinflammatory and autoimmune disease-focused product candidates in various stages of development with the potential to treat many indications.

We are relentless and committed to placing patients at the heart of all we do, and we seek to create life-changing medications.

We are committed to recruiting and retaining a highly qualified workforce with considerable experience and specialized skill sets in the selection, development, and commercialization of transformative treatments.

Whether in development, research, production, technical operations, or general/administrative roles, we rely on a bright team to support our aim of establishing a worldwide, generational business.

Our benefits are competitive, and we provide exciting career opportunities throughout our organization, building a culture that values enthusiasm and swift execution.

Gilead Sciences

Gilead Sciences, Inc. began operations in 1987 in the city of Foster City, California, intending to become one of the most successful biotechnology companies in the United States.

Gilead is a biopharmaceutical company that conducts research, develops, and commercializes innovative medicines.

The company primarily focuses on antiviral drugs that are utilized in the treatment of HIV/AIDS, liver diseases (hepatitis B and hepatitis C), cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

In 2017, the total amount of the company's net income was $4.628 billion. The market capitalization is equal to $90.4 billion.

Amgen Inc.

Formerly known as Applied Molecular Genetics (Amgen Inc), the American international biotechnology business Amgen Inc. currently operates out of its headquarters in Thousand Oaks, California.

It was formed in 1980 to develop novel treatments serving areas of unmet medical need and is the world leader in biopharmaceuticals.

The corporation had a net income of $7.72 billion in the year 2016. Amgen is the most successful biotechnology business in the world in 2018, as reported by Forbes magazine.

Enbrel is an anti-inflammatory medicine that is used to treat rheumatoid arthritis.

Neulasta and Neupogen are closely related drugs that are used to prevent infections during chemotherapy, radiation poisoning, and HIV/AIDS treatment. These three products are the company's key products.

Celgene Corporation

The Celgene Corporation is a competitor operating in the American biotechnology and biopharmaceutical industry. The company's headquarters may be found in Summit, New Jersey.

The pharmaceutical firm was established in 1986, and ever since then, it has been working on the research and development of treatments for inflammatory diseases and cancer.

The net income for Celgene Corporation in 2016 was $2 billion. One of its most important products is Revlimid, which is used to treat multiple myeloma as well as anemia. For the treatment of Myelodysplastic Syndrome, Vidaza is recommended (MDS).

Vertex Pharmaceuticals

A biopharmaceutical company name Vertex Pharmaceuticals, Inc. was established in 1989 in the city of Boston, Massachusetts.

They operate a research facility in California, in the United States, and another research facility in Oxford, in the United Kingdom. One of the first companies in the biotechnology industry to implement a rational drug design method is Vertex.

One of its most important products is An inhibitor of the protease telaprevir is used to treat patients with hepatitis C.

People who have a mutation in the gene that codes for the CFTR protein can be treated for cystic fibrosis with the medicine Orkambi, which is a combination of the lumacaftor and ivacaftor drugs.

Regeneron Pharmaceuticals, Inc

Eastview, New York is the headquarters of the biopharmaceutical business known as Regeneron Pharmaceuticals.

It was established in 1988 with the primary mission of developing and manufacturing medications to address significant unmet medical needs in certain areas.

Additionally, the company has developed a set of patented technologies known as the VelociSuite that may be used for genetic research, the identification of potential therapeutic targets, and the manufacturing of completely human monoclonal antibodies that are specific to tumor and viral antigens.

Its Primary Offerings Consist of: Injections of EYLEA are used to treat neovascular age-related macular degeneration.

ARCALYST for the treatment of particular uncommon autoinflammatory disorders, ZALTRAP for colorectal cancer, If you have a history of familial hypercholesterolemia or clinical atherosclerosis, PRALUENT may be helpful.

A topic dermatitis treatment with DUPIXENT, KEVZARA is used in the treatment of rheumatoid arthritis.

BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc. was established in 1997 and has facilities located in Asia, Europe, and South America in addition to its headquarters in San Rafael, California. BioMarin is known for its work in the research, development, and commercialization of novel biopharmaceuticals for the treatment of uncommon diseases with genetic root causes.

Enzyme replacement medicines are the primary focus of the company. The biopharmaceutical company BioMarin was the first of its kind to offer treatments for mucopolysaccharidosis and phenylketonuria.

The most important ones are: Palynziq and Kuvan are prescribed for patients with phenylketonuria (PKU), Vimizim for Mucopolysaccharidosis IVA, Naglazyme for the treatment of Mucopolysaccharidosis VI, For patients with mucopolysaccharidosis type I, Brineura in the treatment of Batten disease.

Agilent Technologies

Agilent Technologies is a publicly traded research, development, and manufacturing company that was founded in 1999.

The company's headquarters are located in Santa Clara, California, and it offers a variety of products and services, including software, consumables, laboratory supplies, and instruments.

Their areas of expertise include food safety, environmental and forensics issues, pharmaceutical (drug discovery and development), diagnostics and therapeutics, chemical and energy (alternative energy), and research into cancer, cardiovascular diseases, diabetes, Alzheimer's, Parkinson's, autism, and other conditions.

The Company's Primary Offerings are Bioreagents for FISH probes, gas chromatography, and high-performance liquid chromatography, mass spectrometry, immunohistochemistry, microarrays, and target enrichment, Vacuum technology.

Illumina, Inc.

Illumina, Inc. was established in the year 1998 in the city of San Diego, in the state of California.

It is one of the largest biotechnology businesses in the world, and one of its primary focuses is the development of integrated systems for analyzing genetic variation and biological function using sequencing and array-based methodologies.

Whole-genome sequencing, genotyping, gene expression profiling, proteomics, and non-invasive prenatal testing are just some of the products and services that are included in the company's portfolio of goods and offerings (NIPT).

Illumina also sells DNA sequencers. Academic institutions, centers for genomic research, hospitals and clinical research organizations, pharmaceutical and biotechnological firms, and reference laboratories are among its clientele.

Its Most Important Items Are: Integrated systems for the study of genetic variation and biological function using approaches based on sequencing and arrays, DNA sequencer - the company's innovation has contributed to a cost reduction of the sequencing of the human genome from $400,000 to $1 million.

Biogen Inc.

Cambridge, Massachusetts serves as the headquarters for Biogen Inc., which was originally known as Biogen Idec.

It was founded in 1978 in Geneva, Switzerland, but in 2003 it relocated to the United States following a merger with IDEC Pharmaceuticals, which was based in California.

The company's primary focus is on the development, production, and distribution of therapeutic solutions for the management of neurological, hematological, and autoimmune conditions.

This biotechnology corporation had a net income of $2.539 billion for the year 2017.

Its key products include Avonex, Plegridy, Tecfidera, Tysabri, and Fampyra for the treatment of multiple sclerosis; Eloctate and Alprolix for the treatment of hemophilia A and B, respectively; Gazyva and Rituxan for the treatment of chronic lymphocytic leukemia and non-lymphoma, Hodgkin's respectively.

 It is the first monoclonal antibody medication that has been approved by the FDA.

Get The CEO Magazine to your Door Steps; Subscribe Now

Software Suggestion

No stories found.

Best Place to Work

No stories found.

Best Consultants

No stories found.
The CEO Magazine India
www.theceo.in